Replimune Group, Inc. (REPL)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 57,843 | |||
| Selling, general and administrative | 32,579 | |||
| Total operating expenses | 90,422 | |||
| Loss from operations | -90,422 | |||
| Other income (expense) | 591 | |||
| Investment income | 4,714 | |||
| Interest expense on debt obligations | 1,475 | |||
| Interest expense on finance lease liability | 521 | |||
| Research and development incentives | 420 | |||
| Total other income (expense), net | 3,729 | |||
| Net loss | -86,693 | |||
| Net loss per common share, basic (in dollars per share) | -0.95 | |||
| Net loss per common share, diluted (in dollars per share) | -0.95 | |||
| Weighted average common shares outstanding, basic (in shares) | 91,516,199 | |||
| Weighted average common shares outstanding, diluted (in shares) | 91,516,199 | |||